332 related articles for article (PubMed ID: 24743360)
21. Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer.
Schwartzberg L; McIntyre K; Wilks S; Puhalla S; O'Shaughnessy J; Berrak E; He Y; Vahdat L
BMC Cancer; 2019 Jun; 19(1):578. PubMed ID: 31195996
[TBL] [Abstract][Full Text] [Related]
22. Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.
Aftimos P; Polastro L; Ameye L; Jungels C; Vakili J; Paesmans M; van den Eerenbeemt J; Buttice A; Gombos A; de Valeriola D; Gil T; Piccart-Gebhart M; Awada A
Eur J Cancer; 2016 Jun; 60():117-24. PubMed ID: 27107326
[TBL] [Abstract][Full Text] [Related]
23. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer.
Aogi K; Iwata H; Masuda N; Mukai H; Yoshida M; Rai Y; Taguchi K; Sasaki Y; Takashima S
Ann Oncol; 2012 Jun; 23(6):1441-8. PubMed ID: 21989327
[TBL] [Abstract][Full Text] [Related]
24. [Clinical efficacy and safety assessment of eribulin monotherapy in patients with metastatic breast cancer - a single- institute experience].
Hattori M; Fujita T; Sawaki M; Kondo N; Horio A; Ushio A; Gondo N; Idota A; Ichikawa M; Iwata H
Gan To Kagaku Ryoho; 2013 Jun; 40(6):737-41. PubMed ID: 23863649
[TBL] [Abstract][Full Text] [Related]
25. Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.
Park YH; Kim TY; Im YH; Lee KS; Park IH; Sohn J; Lee SH; Im SA; Kim JH; Kim SH; Lee SJ; Koh SJ; Lee KH; Choi YJ; Cho EK; Lee S; Kang SY; Seo JH; Kim SB; Jung KH
Cancer Res Treat; 2017 Apr; 49(2):423-429. PubMed ID: 27488876
[TBL] [Abstract][Full Text] [Related]
26. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.
Wilks S; Puhalla S; O'Shaughnessy J; Schwartzberg L; Berrak E; Song J; Cox D; Vahdat L
Clin Breast Cancer; 2014 Dec; 14(6):405-12. PubMed ID: 25024001
[TBL] [Abstract][Full Text] [Related]
27. A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimens.
Kikuchi Y; Uchida Y; Shirakawa K; Kanauchi H; Niwa T; Nishioka K; Tada K; Hashimoto M; Yasuda H; Sugiura R; Kawabata H; Seto Y; Ogawa T
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e231-e237. PubMed ID: 29498210
[TBL] [Abstract][Full Text] [Related]
28. Eribulin mesylate for the treatment of breast cancer.
Cigler T; Vahdat LT
Expert Opin Pharmacother; 2010 Jun; 11(9):1587-93. PubMed ID: 20450446
[TBL] [Abstract][Full Text] [Related]
29. Eribulin mesylate in advanced breast cancer: retrospective review of a single institute experience.
Martella F; Bacci C; Giordano C; Montagnani F; Gelain E; Rabatti L; Fioretto L
Future Oncol; 2015; 11(15 Suppl):31-6. PubMed ID: 26235263
[TBL] [Abstract][Full Text] [Related]
30. Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer.
Cortes J; Lorca R
Future Oncol; 2011 Mar; 7(3):355-64. PubMed ID: 21375468
[TBL] [Abstract][Full Text] [Related]
31. Safety and tolerability of eribulin mesylate in patients with pretreated metastatic breast cancer.
Goodin S; Barbour S; Song J; Berrak E; Cox D
Am J Health Syst Pharm; 2015 Dec; 72(24):2150-6. PubMed ID: 26637514
[TBL] [Abstract][Full Text] [Related]
32. Phase II Study of Eribulin Mesylate Administered Biweekly in Patients With Human Epidermal Growth Factor Receptor-2-negative Metastatic Breast Cancer.
Smith J; Irwin A; Jensen L; Tedesco K; Misir S; Zhu W; Almonte A; He Y; Xie R; Olivo M; O'Shaughnessy J
Clin Breast Cancer; 2020 Apr; 20(2):160-167. PubMed ID: 31980406
[TBL] [Abstract][Full Text] [Related]
33. A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.
Spira AI; Iannotti NO; Savin MA; Neubauer M; Gabrail NY; Yanagihara RH; Zang EA; Cole PE; Shuster D; Das A
Clin Lung Cancer; 2012 Jan; 13(1):31-8. PubMed ID: 21862415
[TBL] [Abstract][Full Text] [Related]
34. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
Cortes J; O'Shaughnessy J; Loesch D; Blum JL; Vahdat LT; Petrakova K; Chollet P; Manikas A; Diéras V; Delozier T; Vladimirov V; Cardoso F; Koh H; Bougnoux P; Dutcus CE; Seegobin S; Mir D; Meneses N; Wanders J; Twelves C;
Lancet; 2011 Mar; 377(9769):914-23. PubMed ID: 21376385
[TBL] [Abstract][Full Text] [Related]
35. Activity of eribulin mesylate in heavily pretreated breast cancer granted access via the Cancer Drugs Fund.
Ramaswami R; O'Cathail SM; Brindley JH; Silcocks P; Mahmoud S; Palmieri C
Future Oncol; 2014 Feb; 10(3):363-76. PubMed ID: 24367990
[TBL] [Abstract][Full Text] [Related]
36. Eribulin: Heavily pretreated breast cancer: uncertain advantages, excessive adverse effects.
Prescrire Int; 2012 Feb; 21(124):37-8. PubMed ID: 22413716
[TBL] [Abstract][Full Text] [Related]
37. Phase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer.
Mukai H; Saeki T; Shimada K; Naito Y; Matsubara N; Nakanishi T; Obaishi H; Namiki M; Sasaki Y
Invest New Drugs; 2015 Feb; 33(1):119-27. PubMed ID: 25242374
[TBL] [Abstract][Full Text] [Related]
38. Retrospective analysis of the efficacy and safety of eribulin therapy for metastatic breast cancer in daily practice.
Tanaka T; Ueno M; Nakashima Y; Chinen S; Sato E; Masaki M; Mogi A; Sasaki H; Tamura K; Takamatsu Y
Thorac Cancer; 2017 Sep; 8(5):523-529. PubMed ID: 28741868
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.
Maeda S; Saimura M; Minami S; Kurashita K; Nishimura R; Kai Y; Yano H; Mashino K; Mitsuyama S; Shimokawa M; Tamura K;
Breast; 2017 Apr; 32():66-72. PubMed ID: 28056400
[TBL] [Abstract][Full Text] [Related]
40. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.
McBride A; Butler SK
Am J Health Syst Pharm; 2012 May; 69(9):745-55. PubMed ID: 22517020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
